Adinazolam is primarily studied in preclinical and academic settings for its pharmacological similarities to classical benzodiazepines. Though never widely released for therapeutic use, it has attracted significant attention in research due to its unique chemical structure and effect profile. It is structurally categorized as a thienodiazepine and functions as a GABA-A receptor positive allosteric modulator, making it valuable in understanding anxiety, sedation, and receptor-binding dynamics in the CNS.

• Anxiolytic Mechanism Studies
  Researchers use Adinazolam to model anti-anxiety (anxiolytic) effects in animal subjects. It is studied for how it facilitates GABAergic neurotransmission, potentially reducing central excitability and stress responses.

• GABA-A Receptor Affinity Research
  As a ligand at the benzodiazepine binding site on the GABA-A receptor, it helps elucidate receptor subunit specificity, which is important in understanding pharmacological selectivity.

• Sedative-Hypnotic Testing
  Adinazolam has been observed to induce sedative states in rodent models. These results are used to assess sedation thresholds and duration compared to other analogs.

• Structure-Activity Relationship (SAR) Analysis
  Its molecular design—a fusion of triazole and thienodiazepine backbones—makes it useful in SAR studies that map how molecular changes influence receptor binding and potency.

• Pharmacokinetic Profiling
  Adinazolam is investigated for its absorption rate, half-life, and metabolic breakdown, typically via in vitro assays or rodent plasma concentration tracking.

• Comparative Benzodiazepine Studies
  It is often compared with diazepam, alprazolam, and other benzodiazepines to assess relative potency, onset of action, and therapeutic windows.

• Neuropharmacology Education
  In academic settings, Adinazolam serves as a teaching compound to demonstrate CNS depressant pharmacodynamics and chemical classification within non-standard benzodiazepines.

Adinazolam is generally classified as unscheduled, meaning it is not explicitly listed under most national or international drug control treaties. However, legality can vary significantly depending on the region or local authority. As such, researchers must exercise diligence in verifying compliance before import or use.

• Not Scheduled Under the U.S. CSA
  As of the latest updates, Adinazolam is not listed as a controlled substance under the U.S. Controlled Substances Act, though analog laws may apply depending on intent.

• Research-Only Use Is Permitted
  In most regions, possession and use are permitted for analytical, preclinical, or educational purposes only. Human consumption or clinical use is strictly prohibited.

• Analog Laws in Certain Jurisdictions
  Countries like the U.S., U.K., and Australia enforce analogue laws where structurally similar compounds may be regulated if intended for consumption.

• Documentation and Labeling Compliance
  RC Plug ships Adinazolam with appropriate “not for human consumption” and “for research use only” labels to comply with common regulatory requirements.

• Customer Due Diligence Required
  We urge all buyers to verify the legal classification in their respective countries or states, particularly when importing for institutional use.

• No Prescription Required for Purchase
  Since Adinazolam is not a pharmaceutical product, a medical prescription is neither required nor accepted for research supply.

Adinazolam exhibits moderate potency in animal models when compared to common clinical benzodiazepines. It shows significant anxiolytic and sedative effects but with a milder intensity and shorter duration compared to compounds like alprazolam or clonazolam. Its unique thienodiazepine structure results in slightly different pharmacodynamics.

• Milder Than Alprazolam
  In most comparative studies, Adinazolam exhibits lower potency than alprazolam, requiring a slightly higher dose to achieve similar GABAergic modulation.

• Shorter Duration of Action
  Its half-life, typically between 3–6 hours, is shorter than that of diazepam or clonazolam, making it suitable for acute, time-restricted experiments.

• High Selectivity at GABA-A Sites
  Adinazolam may bind more selectively to certain GABA-A receptor subtypes, contributing to focused anxiolytic action with less sedation than broader-spectrum agents.

• Less Accumulation Risk
  Due to limited active metabolites and a shorter duration, Adinazolam poses less risk of cumulative receptor saturation in repeated dosing models.

• Low to Moderate Tolerance Development (In Theory)
  Although not extensively documented, its moderate potency may lead to slower tolerance buildup in longitudinal research models compared to more potent analogs.

• Potential for Precision Testing
  Its balanced activity makes it ideal for studies that require specific anxiolytic or sedative thresholds without overpowering effects.

Proper storage of Adinazolam is essential to preserving its chemical stability and experimental integrity. Like most fine organic compounds, it is sensitive to environmental stressors such as moisture, heat, and light. Researchers must follow optimal storage protocols to prevent degradation over time.

• Store at or Below 25°C (77°F)
  Room temperature is acceptable, but cooler environments extend shelf life and minimize compound breakdown.

• Use a Dry, Airtight Container
  Moisture can compromise the crystalline structure and purity. Always store Adinazolam in desiccated containers to maintain integrity.

• Keep Away from Light Exposure
  Direct UV or fluorescent light can lead to photodegradation. Use opaque or amber glass containers to block harmful rays.

• Avoid Frequent Reopening
  Exposure to ambient humidity during repeated use should be minimized. Retrieve only the amount needed per experiment to avoid compromising the bulk compound.

• No Freezing Necessary
  Unlike some compounds, freezing Adinazolam is not recommended as temperature fluctuations can introduce condensation upon thawing.

• Desiccants Recommended
  Including silica gel or molecular sieves inside the storage vessel helps maintain low humidity levels inside the container.

• Stability Timeline
  Under these optimal conditions, Adinazolam can remain stable and effective for up to 12–18 months, with regular re-testing advised for long-term storage.

When handled under appropriate laboratory conditions, Adinazolam poses minimal risk. However, as with all psychoactive or CNS-affecting compounds, strict handling precautions are necessary to ensure researcher safety and prevent contamination. It should only be manipulated in certified lab environments by trained personnel.

• Personal Protective Equipment (PPE) Required
  Use gloves, eye protection, and lab coats during all stages of handling to avoid skin or eye contact.

• Use in a Fume Hood
  Always weigh, dissolve, or transfer the compound under a chemical fume hood to prevent inhalation of airborne particulates.

• Avoid Ingestion and Inhalation
  This compound is not intended for human use. Accidental inhalation or ingestion may result in harmful CNS effects.

• Wash Hands Thoroughly
  After handling, ensure all surfaces are cleaned and hands are thoroughly washed—even if gloves were used.

• Proper Spill Protocols
  In case of accidental spillage, absorb the compound using appropriate lab absorbents and dispose of waste according to institutional chemical safety guidelines.

• Access Controls Advised
  Store the compound in a locked cabinet or access-restricted area to prevent unauthorized exposure.

• Refer to Safety Data Sheet (SDS)
  Always review the SDS for detailed toxicological data, first-aid measures, and physical/chemical hazard information.

Adinazolam’s solubility profile is a critical factor in research involving solution-based assays, receptor-binding studies, or in vivo dosing. It exhibits poor water solubility, which makes it less suitable for purely aqueous formulations. However, it dissolves effectively in several organic solvents commonly used in laboratory settings. Researchers must carefully select the appropriate solvent based on experimental requirements, compatibility, and safety guidelines.

• Limited Aqueous Solubility
  Adinazolam does not dissolve well in water due to its lipophilic (fat-soluble) molecular structure, which lacks the polarity needed for effective dispersion in aqueous environments.

• Soluble in Ethanol and DMSO
  Ethanol (EtOH) and dimethyl sulfoxide (DMSO) are the most effective solvents for Adinazolam dissolution, with fast and complete solubilization at room temperature.

• Use of Co-Solvent Systems
  Some researchers prepare solutions using a mix of ethanol and PEG-400 or propylene glycol to increase solubility while reducing cytotoxicity in cell cultures or in vivo experiments.

• Sonication May Help
  Applying ultrasonic agitation can assist in breaking down powder clumps and promoting faster, more even dissolution in solvents.

• Avoid Highly Acidic or Basic Media
  Adinazolam may degrade in strongly acidic or alkaline conditions, making pH-neutral or slightly buffered solvents more suitable.

• Prepare Fresh Solutions When Possible
  To prevent degradation or precipitation over time, it’s best to prepare solutions immediately before use or store them under controlled conditions if needed.

• Sterile Filtration for Injectable Studies
  If used in animal models via parenteral routes, researchers often pass the dissolved solution through a 0.2 µm filter for sterility without affecting the compound.

Understanding Adinazolam’s half-life is important for research exploring drug dynamics, CNS receptor modulation timing, or designing dose-response experiments. In preclinical rodent models and in vitro metabolic studies, Adinazolam demonstrates a short-to-moderate half-life compared to other benzodiazepine analogs.

• Estimated Half-Life of 3 to 6 Hours
  Based on existing animal data and pharmacokinetic estimations, Adinazolam is rapidly metabolized with a moderate duration of action.

• Supports Acute Experimental Design
  The half-life makes it suitable for short-term or acute-effect modeling where extended sedation is not ideal.

• Low Risk of Accumulation
  Because of its relatively brief half-life and minimal active metabolite production, Adinazolam does not tend to accumulate significantly with repeated short-term use.

• Useful for Time-Course Studies
  Its intermediate duration allows researchers to track neurochemical or behavioral changes within a clear, manageable window of 4–8 hours.

• Comparatively Shorter than Diazepam
  Unlike diazepam, which may linger for 24+ hours, Adinazolam clears from systems faster, offering cleaner endpoints in single-dose research.

• Minor Role of Metabolites
  While N-desmethyladinazolam is its main metabolite, it exhibits much weaker activity and contributes minimally to total pharmacological effects.

Yes. Every Adinazolam order from RC Plug is shipped with a Certificate of Analysis (COA) that confirms product identity, purity, and compliance with analytical testing standards. This documentation is critical for reproducibility, batch verification, and institutional compliance in research labs.

• COA Confirms ≥98% Purity
  All Adinazolam supplied by RC Plug is tested and confirmed to meet or exceed 98% purity via validated analytical methods.

• Analytical Methods Clearly Stated
  Our COA includes detailed testing methodology such as high-performance liquid chromatography (HPLC), gas chromatography-mass spectrometry (GC-MS), and/or nuclear magnetic resonance (NMR).

• Batch Number and Production Date
  Each COA includes the compound’s batch number, manufacture date, and recommended retest date, ensuring traceability.

• Issued by Certified Labs
  Testing is performed by accredited third-party laboratories to ensure unbiased results.

• Digital and Physical Copies
  COAs are sent electronically upon purchase and also included in the package as hard copies, for reference during inventory or audits.

• Ensures Research Validity
  This documentation is essential for researchers who must adhere to internal quality control systems or publish data based on verified material.

RC Plug is proud to offer international shipping for Adinazolam to most countries where it is legally permitted for research purposes. We have extensive experience handling customs and regulatory protocols to ensure our shipments arrive securely and intact.

• Worldwide Shipping Available
  We dispatch to North America, Europe, Asia, Africa, and Oceania, provided local regulations do not restrict Adinazolam’s import.

• Discreet Packaging for All Orders
  All parcels are packed in plain, unbranded materials that do not disclose product names or content specifics.

• Labeled for Research Use Only
  Shipments are marked clearly as “not for human consumption” and “for laboratory use only” to comply with most customs declaration rules.

• Tracking Number Provided
  Customers receive a tracking number within 24 hours of dispatch to monitor delivery progress.

• Assistance with Customs Delays
  In rare cases of customs holds, our support team provides documentation and helps facilitate release or offers a replacement per our policy.

• Customer Responsibility for Legal Compliance
  Buyers are expected to confirm the product’s legal status in their country prior to purchase. RC Plug cannot intervene in jurisdictions where the compound is restricted.

No, a prescription is not required to purchase Adinazolam from RC Plug. We supply this compound strictly for research purposes and do not operate under pharmaceutical or clinical guidelines. This simplifies access for academic and private laboratories that need high-quality materials without administrative barriers.

• No Medical License Required
  Purchases can be made by research teams, universities, and qualified individuals without presenting a prescription or DEA license.

• Research-Use Only Classification
  Adinazolam is sold solely for non-clinical purposes and is clearly labeled as such on all documentation and packaging.

• Not for Human Consumption
  We do not support or condone any use of Adinazolam outside of analytical or laboratory environments.

• Open to Institutional Buyers Worldwide
  Universities, contract research organizations (CROs), and scientific institutions can order Adinazolam with ease using bank transfers or crypto payments.

• No Questions Asked on Research Type
  While we advise following all applicable laws, we do not require disclosure of specific experiments or study designs when ordering.

Adinazolam is not approved for clinical or therapeutic use in any country. It was initially investigated as a potential anxiolytic agent but was never commercialized or authorized for human treatment. All current availability of Adinazolam is strictly limited to research purposes only, and any clinical application would be considered unauthorized and potentially dangerous.

• No FDA or EMA Approval
  Adinazolam was never submitted or approved by the U.S. Food and Drug Administration (FDA) or European Medicines Agency (EMA) for any medical indication.

• Lack of Clinical Trials
  There are no completed or ongoing human clinical trials assessing its safety, efficacy, or dosing in therapeutic populations, limiting its use to preclinical models.

• Sold for Research Use Only
  RC Plug and similar suppliers explicitly label Adinazolam as “not for human consumption” and prohibit any therapeutic administration.

• Potential Legal and Ethical Risks
  Using Adinazolam in a clinical or self-experimentation context could violate drug laws and research ethics in most countries.

• Unknown Safety Profile in Humans
  Without rigorous clinical testing, its pharmacological effects, side effects, interactions, and toxicity in humans remain speculative and potentially hazardous.

• Institutional Policies Prohibit Clinical Use
  Research institutions that comply with IRB (Institutional Review Board) standards do not permit unapproved substances for clinical or patient-oriented research.

Yes, Adinazolam is known to undergo biotransformation, resulting primarily in one active metabolite: N-desmethyladinazolam. This metabolic process has been studied in both animal liver microsome assays and limited pharmacokinetic evaluations. Understanding its metabolites is crucial in research focused on receptor activity, half-life analysis, and CNS drug clearance.

• N-Desmethyladinazolam Is the Primary Metabolite
  It results from hepatic demethylation and retains some GABAergic activity, although its potency is significantly lower than the parent compound.

• Metabolism Occurs Primarily in the Liver
  Like many benzodiazepine analogs, Adinazolam is metabolized by cytochrome P450 enzymes, particularly CYP3A isoforms.

• Short-Lived Active Effects
  The metabolite exhibits a relatively short half-life and contributes only modestly to the pharmacodynamic effects seen in animal models.

• Minimal Toxic Metabolites
  Studies have not identified any highly toxic breakdown products, which supports its use in short-term animal or in vitro studies.

• Useful in Metabolite Mapping Research
  Researchers examining drug metabolism pathways use Adinazolam to understand minor structural changes and their effect on CNS penetration or receptor binding.

• Low Interference in Binding Assays
  The weak activity of N-desmethyladinazolam makes it less likely to interfere in receptor affinity studies when assessing the parent compound.

In theory, Adinazolam may pose dependence and tolerance risks, similar to other compounds in the benzodiazepine or thienodiazepine class. However, such effects have not been documented in human subjects due to its lack of clinical testing. Nonetheless, in rodent models and mechanistic studies, researchers observe behavioral and neurochemical signs consistent with substances that interact with GABA-A receptors.

• Binds at GABA-A Benzodiazepine Site
  As a positive allosteric modulator, Adinazolam increases GABA-A receptor activity, which is a common mechanism behind sedative and dependence-forming effects.

• Tolerance Development in Repeated Dosing
  In repeated-dose studies on rodents, there is evidence of decreasing effectiveness over time, indicating potential for tolerance.

• Withdrawal Potential Exists
  Sudden discontinuation after repeated exposure in animal models has shown hyperexcitability and agitation—behaviors associated with withdrawal.

• Not Safe for Recreational Use
  Given its CNS-modulating properties, using Adinazolam outside of a lab environment poses serious health risks and addiction potential.

• No Documented Human Cases
  Since it was never widely marketed or consumed, there are no real-world reports of Adinazolam addiction or abuse—though this does not eliminate the risk.

• Valuable for Addiction Research
  Due to its structure and receptor profile, Adinazolam may serve as a model compound in addiction liability or dependency mechanism studies.

While Adinazolam shares many effects with traditional benzodiazepines, it is chemically distinct as a thienodiazepine. This subclass substitution introduces structural and possibly functional variations, making it an important candidate for comparative studies. These differences influence its binding dynamics, potency, and receptor subtype selectivity.

• Thienodiazepine Core Instead of Benzodiazepine
  The presence of a thiophene ring instead of a benzene ring in its backbone gives Adinazolam distinct physicochemical and pharmacokinetic properties.

• Contains a Triazolo Ring
  Similar to alprazolam and triazolam, Adinazolam contains a triazolo moiety, which may affect receptor affinity and CNS penetration.

• Different Receptor Subunit Affinity
  Research suggests possible variations in binding to GABA-A subunits, which could explain differences in sedation vs. anxiolysis ratio.

• Faster Onset with Shorter Duration
  Compared to long-acting benzos like diazepam, Adinazolam has a faster onset and shorter half-life, making it more appropriate for acute studies.

• Less Understood Metabolic Pathways
  Because it was never approved for clinical use, its complete metabolic profile is less characterized than drugs like clonazepam or lorazepam.

• Useful in Structure-Activity Relationship Studies
  Its distinct core structure provides a scaffold for examining how minor changes in molecular configuration impact CNS drug behavior.

Adinazolam typically appears as an off-white to light beige crystalline powder, which is characteristic of many organic psychoactive compounds. Its visual and physical properties provide basic indicators of identity and purity, although confirmation through spectroscopy is always necessary for research use.

• Crystalline and Fine Powder
  The compound is usually delivered in a dry, free-flowing crystalline state that is easy to handle in microgram to gram-scale quantities.

• Color May Vary Slightly
  Depending on synthesis route and residual solvents, the color may range from pure white to slightly yellowish or beige, though purity remains consistent.

• No Distinct Odor
  Adinazolam is odorless or may carry a very faint solvent smell if residuals are present post-synthesis.

• Microscopically Homogeneous
  When viewed under a microscope, the particle size is consistent, aiding in accurate dosing and dilution for research.

• Not Hygroscopic Under Normal Conditions
  The powder does not easily absorb moisture unless left exposed to high humidity environments.

• Physical Appearance Is Not a Purity Guarantee
  While visual inspection may indicate batch uniformity, full identification must be done using COA-verified analytical methods such as HPLC or NMR.

Combining Adinazolam with other research chemicals (RCs) should only be done with great caution and under strict laboratory conditions. While polypharmacological studies are valuable for understanding compound interactions, unregulated or poorly controlled combinations can result in unpredictable outcomes, including receptor competition, synergistic sedation, or metabolic interference.

• GABAergic Synergy Risks
  Combining Adinazolam with other GABA-A agonists or modulators (e.g., Clonazolam, Etizolam) can amplify sedation and respiratory depression in animal models.

• Increased Complexity in Behavioral Studies
  Co-administration with stimulants, dissociatives, or serotonergic compounds complicates data interpretation due to overlapping neurochemical effects.

• Potential for Receptor Competition
  If combined with another compound that binds to the same receptor site, Adinazolam’s efficacy may be reduced or altered in unexpected ways.

• Metabolic Interactions Are Possible
  Compounds metabolized via CYP450 enzymes may either induce or inhibit Adinazolam metabolism, affecting its concentration and half-life in systemic circulation.

• Useful for Interaction Modeling
  Despite the risks, such combinations are studied to simulate polypharmacy, especially in neuropsychopharmacology and toxicity screening.

• Requires Controlled Dosing Regimens
  Experimental protocols involving more than one compound must include tightly regulated doses and intervals to minimize unpredictable pharmacodynamics.

• Not Recommended Without Institutional Oversight
  Only accredited labs should conduct combination studies, ideally under internal review or ethical guidelines for animal research.